

Metacam 

Previcox 

TRUSTED PAIN RELIEF FOR PETS BIG AND SMALL





**EFFECTIVE
ANTI-INFLAMMATORY
PAIN RELIEF FOR
DOGS, CATS AND
GUINEA PIGS**




Trust the Metacam® range for all your patient needs



Relieves pain and inflammation
resulting from*:

- Soft tissue and orthopaedic surgery
- Acute musculoskeletal disease
- Chronic musculoskeletal disease



Relieves pain and
inflammation resulting from*:

- Soft tissue and orthopaedic surgery
- Acute musculoskeletal disease
- Chronic musculoskeletal disease



Relieves pain and increases
appetite following:

- Soft tissue surgery

*Range of indications are across the Metacam® range. For individual product indications, consult the package insert.

Metacam 

 Previcox

Why choose Metacam®?



Easy to Give
isfm Approved



Metacam® is **proven**



Metacam® is **precise**



Metacam® is **flexible**




A winning partnership against pain

Previcox[®]

**FAST-ACTING,
SUSTAINED
PAIN RELIEF¹⁻³**




Why choose Previcox®?



The most highly selective veterinary COX-2 inhibitor^{4,7-9}



Only marketed NSAID licensed for all surgery, including dental



Fast, effective and sustained pain & inflammation relief¹⁻⁶



Accurate dosing



Easy administration

A winning partnership against pain

A winning partnership for tailored pain solutions



LICENSED USE: MUSCULOSKELETAL DISEASE	ACUTE (TRAUMA) PAIN AND INFLAMMATION		—
	CHRONIC (OSTEOARTHRITIS) PAIN AND INFLAMMATION		
LICENSED USE: SURGERY	SOFT TISSUE		
	ORTHOPAEDIC		
	DENTAL	—	
SAFETY AND EFFICACY	THROUGH CLINICAL STUDIES AND IN-CLINIC USE OVER ¹⁰⁻²³		
	FOR PERIOPERATIVE PAIN ¹⁰⁻¹⁵		
	FOR LONG-TERM USE FOR CHRONIC PAIN ¹⁶⁻²³		
FORMULATION	INJECTABLE		—
	ORAL SUSPENSION		—
	TABLET		
ONSET AND DURATION OF ACTION	REDUCTION IN LAMENESS IN ACUTE MODELS OF OSTEOARTHRITIS WITH ORAL MEDICATION ^{3,24}	 45% at 4 h, 71% at 6 h Best outcome when treatment begins with injectable ²⁵	 RAPID: 72% at 3 h, 99% at 7 h
	CONSISTENT 24-HOUR ACTION WITH STEADY STATE IN ²⁶	 2 days 2 days	 3 days
SUPPORT	TAILOR-MADE SERVICES SUPPORT		

References

1. Ryan W.G., Moldave K., Carithers D. (2006) Clinical effectiveness and safety of a new NSAID, firocoxib: a 1,000 dog study. *Vet Ther.* 7:119–126.
2. Drag M., Kunkle B.N., Romano D., Hanson P.D. (2007) Efficacy of firocoxib in preventing urate induced synovitis, pain, and inflammation in dogs. *Vet Ther.* 8:41–50.
3. Hazewinkel HA, van den Brom WE, Theyse LF, et al. Comparison of the effects of firocoxib, carprofen, and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs. *Res Vet Sci.* 2008;84:74–79.
4. McCann, ME, *et al.* In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. *Am J Vet Res.* 2004;65(4):503–512.
5. Dauteloup C., *et al.* Assessment of the efficacy of firocoxib and robenacoxib in an induced synovitis model of acute arthritis in dogs. *Intern J Appl Res Vet Med.* 2017;15(1).
6. Autefage, A., *et al.* Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis, *Vet Rec.* 2011; 168: 617
7. Onsior® EPAR Scientific Discussion. King J.N., Rudaz C., Borer L., et al. In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. *Res Vet Sci.* 2010;88:497–506.
8. Trocoxil® Summary of Product Characteristics (SPC).
9. Solà J, et al. Selective inhibition of cyclooxygenase-2 by enflicoxib, its enantiomers and its main metabolites in vitro in canine blood. *J Vet Pharmacol Ther.* 2022 May;45(3):235-244.
10. Höhner F. Safety and efficacy of Meloxicam (METACAM®) for the use as a perioperative analgesic in 3714 dogs. *Praktische Tierarzt.* 2004;85:328–334.
11. Crandell DE, Mathews KA, Dyson DH. Effect of meloxicam and carprofen on renal function when administered to healthy dogs prior to anesthesia and painful stimulation. *Am J Vet Res.* 2004;65:1384–1390.
12. Slingsby LS, Waterman-Pearson AE. Comparison between meloxicam and carprofen for postoperative analgesia after feline ovariohysterectomy. *J Small Anim Pract.* 2002;43:286–289.
13. Kondo Y, Takashima K, Matsumoto S, *et al.* Efficacy and safety of firocoxib for the treatment of pain associated with soft tissue surgery in dogs under field conditions in Japan. *J Vet Med Sci.* 2012;74:1283–1289.
14. Camargo JB, Steagall PV, Minto BW, Lorena SE, Mori ES, Luna SP. Post-operative analgesic effects of butorphanol or firocoxib administered to dogs undergoing elective ovariohysterectomy. *Vet Anaesth Analg.* 2011;38:252–259.

References

15. Davila D, Keeshen TP, Evans RB, Conzemius MG. Comparison of the analgesic efficacy of perioperative firocoxib and tramadol administration in dogs undergoing tibial plateau levelling osteotomy. *J Am Vet Med Assoc.* 2013;243:225–231.
16. Doig PA, Purbrick KA, Hare JE, McKeown DB. Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis. *Can Vet J.* 2000;41:296–300.
17. Peterson KD, Keefe TJ. Effects of meloxicam on severity of lameness and other clinical signs of osteoarthritis in dogs. *J Am Vet Med Assoc.* 2004;225:1056–1060.
18. Clarke SP, Bennett D. Feline osteoarthritis: a prospective study of 28 cases. *J Small Anim Pract.* 2006;47:439–445.
19. Gunew M, Menrath V, Marshall R. Long-term safety, efficacy and palatability of oral meloxicam at 0.01–0.03 mg/kg for treatment of osteoarthritic pain in cats. *J Feline Med Surg.* 2008;10:235–241.
20. Pollmeier M, Toulemonde C, Fleishman C, Hanson PD. Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis. *Vet Rec.* 2006;159:547–551.
21. Hanson PD, Brooks KC, Case J, *et al.* Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions. *Vet Ther.* 2006;7:127–140.
22. Lecoindre O, Pepin-Richard C. Tolerance of firocoxib in dogs with osteoarthritis during 90 days. *J Vet Pharmacol Ther.* 2010;34:190–192.
23. Joubert KE. The effects of firocoxib (PREVICOX) in geriatric dogs over a period of 90 days. *J S Afr Vet Assoc.* 2009;80:179–184.
24. Borer LR, Peel JE, Seewald W, Schawalder P, Spreng DE. Effect of carprofen, etodolac, meloxicam, or butorphanol in dogs with induced acute synovitis. *Am J Vet Res.* 2003;64:1429–1437.
25. Metacam® (meloxicam). An overview of Metacam® and why it is authorised in the EU. European Medicines Agency website. <https://www.ema.europa.eu/en/documents/> Accessed November 2023.
26. Borer-Weir K. Analgesia. In: Clarke KW, Trim CM, Hall LW, eds. *Veterinary Anaesthesia.* 11th ed. Philadelphia, PA: W.B. Saunders; 2014:101–133.

Metacam® contains meloxicam. Previcox® contains firocoxib. UK: POM-V IE: POM. Further information available in the SPCs or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email: vetenquiries@boehringer-ingelheim.com. Metacam® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. Previcox® is a registered trademark of Boehringer Ingelheim Animal Health France SCS, used under licence. ©2023 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Nov 2023. UI-CAN-0133-2023. Use Medicines Responsibly.